Mainz Biomed BV

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer process New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer process

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable investor conferences in May, 2022, the H.C. Wainwright Global Investment Conference and the Equity Forum German Spring Conference.

Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

BERKELEY, Calif. and MAINZ, Germany, May 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will bring together key opinion leaders (KOLs) from across the Colorectal Cancer (CRC) screening and diagnostics community in an event to be held during Digestive Disease Week (DDW 2022) in San Diego, California.

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

BERKELEY, Calif. and MAINZ, Germany, May 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that PancAlert, its screening test candidate for pancreatic cancer has achieved multiple pre-clinical milestones that support the development of this potential first-in-class diagnostic for a deadly cancer indication.

Mainz Biomed Provides Product Development Update on PancAlert

Former Abbott and Luminex executive with over 30 years of In Vitro Diagnostic (IVD) and life science research experience appointed to execute the international commercialization of ColoAlert and drive the development of the Mainz Biomed's portfolio of cancer detection products Former Abbott and Luminex executive with over 30 years of In Vitro Diagnostic (IVD) and life science research experience appointed to execute the international commercialization of ColoAlert and drive the development of the Mainz Biomed's portfolio of cancer detection products

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today operational results for the first quarter ended March 31, 2022.

Mainz Biomed Announces First Quarter 2022 Results

BERKELEY, Calif. and MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has received supportive feedback from the U.S. Food & Drug Administration (FDA) on the Company's pre-submission package profiling the potential pivotal clinical trial design for ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). As Mainz prepares to launch ColoAlert's pivotal clinical trial, the Company is also pleased to announce the formal commencement of its reimbursement process for ColoAlert by scheduling an initial meeting with The Centers for Medicare and Medicaid Services (CMS) in April 2022. The CMS is a federal agency in the U.S. Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program (CHIP), and health insurance portability standards.

Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert's Pivotal Clinical Trial

BERKELEY, Calif. and MAINZ, Germany, March 21, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer, will ring the closing bell at Nasdaq MarketSite in New York's Times Square today, Monday, March 21st, 2022 at 4:00 pm ET. The Company commenced trading on the Nasdaq Stock Market under the ticker symbol “MYNZ” on November 8th, 2021.

Mainz Biomed to Ring Nasdaq Stock Market Closing Bell

- ColoFuture on track to complete enrollment in 2H 2022 -

Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study

BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today key strategic and operational results for the year ended December 31, 2021.

Mainz Biomed Announces Year End 2021 Results

Mainz Biomed joins a collective of physicians, healthcare professionals, laboratories and healthcare organizations as part of the international Colorectal Cancer Awareness Month initiative

Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month

Pivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug Administration Pivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug Administration

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

BERKELEY, Calif. and MAINZ, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Labor MVZ Dr. Stein + Kollegen (“Laboratory Mönchengladbach”). Laboratory Mönchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomed's unique, highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

Former DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry

Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board

Results to impact ColoAlert profile for FDA submission

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert's FDA Submission Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert's FDA Submission

Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Highly experienced diagnostics business development executive appointed to lead growth initiatives across international markets and drive international sales of ColoAlert at-home screening test for Colorectal Cancer Highly experienced diagnostics business development executive appointed to lead growth initiatives across international markets and drive international sales of ColoAlert at-home screening test for Colorectal Cancer

Mainz Biomed Appoints Steve Quinn as VP Business Development

The molecular genetics diagnostic company announced the pricing of a follow-on stock offering.

Why Mainz Biomed Stock Is Crashing Today

Mainz Biomed has filed Form F-1 to raise ~$41 million gross proceeds from 1.5M shares.

Mainz Biomed: Sharp Appreciation In Value Since IPO

BERKELEY, Calif. and MAINZ, Germany, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the pricing of its underwritten public follow-on offering (the “Follow-on Offering”) of 1,500,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the “Offering Price”), for gross proceeds of $22,500,000.

Mainz Biomed Announces Pricing of Follow-on Offering

Results of European study potentially incorporated into U.S. regulatory strategy for FDA approval

Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

BERKELEY, Calif. and MAINZ, Germany, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Michele Pedrocchi to its Strategic Advisory Board.

Mainz Biomed Appoints Michele Pedrocchi, Former Head of Roche Diagnostics Business Development, to Strategic Advisory Board

BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference taking place on January 10-13, 2022.

Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference

Mainz Biomed N.V. (NASDAQ: MYNZ) went up by 80% after it announced that it and Socpra Sciences had executed a Technology Rights Agreement in order to gain access to novel mRNA biomarkers with the goal of integrating them into ColoAlert in the future.

News for Mainz Biomed BV Stock (MYNZ)